Australia markets closed

Viridian Therapeutics, Inc. (VRDN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
19.00+0.56 (+3.04%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close18.44
Open18.64
Bid16.35 x 1100
Ask23.98 x 800
Day's range17.86 - 19.00
52-week range10.44 - 25.67
Volume38,582
Avg. volume232,017
Market cap412.724M
Beta (5Y monthly)1.10
PE ratio (TTM)N/A
EPS (TTM)-19.21
Earnings date08 Nov 2021 - 12 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est35.25
  • GlobeNewswire

    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WALTHAM, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by current therapies, today announced that a majority of the independent directors serving on the Company’s Board of Directors approved the grant of stock options to purchase an aggregate of 180,000 shares of the Company’s common stock to two new employees (the “Ind

  • GlobeNewswire

    Viridian Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for VRDN-001, an IGF-1R Antibody for the Treatment of Thyroid Eye Disease (TED)

    Phase 1/2 proof of concept trial for VRDN-001 is expected to report top line clinical data in the second quarter of 2022 WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN) (the “Company” or “Viridian”), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the U.S. Food and Drug Administration (“FDA”) clearance of its Investigational New Drug (“IND”) application for

  • GlobeNewswire

    Viridian Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

    Submitted an investigational new drug (IND) application to the FDA for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease (TED) and expect to report Phase 1/2 proof of concept clinical data in TED patients in the second quarter of 2022 VRDN-002, a distinct IGF-1R antibody incorporating validated half-life extension technology, remains on track for an IND filing before year end 2021, and to deliver initial clinical data in mid-2022Strong financial position after successful foll